Review
. 2014 Apr;110(1).
doi: 10.1002/jso.23609.

The importance of systemic therapy in minimizing local recurrence after breast-conserving surgery: the NSABP experience

Eleftherios P Mamounas 1 Gong Tang  Qing Liu  
Affiliations
  • PMID: 24729388
  •     35 References
  •     8 citations

Abstract

Adjuvant systemic therapy significantly reduces rates of distant recurrence and death. The effect of systemic therapy is not limited to reducing distant recurrences but also extends to reducing loco-regional recurrences, and rates of loco-regional recurrence have steadily declined over the past 25 years. This review focuses on the effect of adjuvant systemic therapy on rates of ipsilateral breast tumor recurrence following lumpectomy plus breast irradiation in several pivotal NSABP trials in early-stage breast cancer.

Keywords: adjuvant systemic therapy; ipsilateral breast tumor recurrence; lumpectomy.

Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer.
Martine J Piccart-Gebhart, Marion Procter, +30 authors, Herceptin Adjuvant (HERA) Trial Study Team.
N Engl J Med, 2005 Oct 21; 353(16). PMID: 16236737
Highly Cited.
Adjuvant trastuzumab in HER2-positive breast cancer.
Dennis Slamon, Wolfgang Eiermann, +21 authors, Breast Cancer International Research Group.
N Engl J Med, 2011 Oct 14; 365(14). PMID: 21991949    Free PMC article.
Highly Cited.
erbB-2 and response to doxorubicin in patients with axillary lymph node-positive, hormone receptor-negative breast cancer.
S Paik, J Bryant, +7 authors, N Wolmark.
J Natl Cancer Inst, 1998 Sep 25; 90(18). PMID: 9747867
HER2 and choice of adjuvant chemotherapy for invasive breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-15.
S Paik, J Bryant, +4 authors, N Wolmark.
J Natl Cancer Inst, 2000 Dec 21; 92(24). PMID: 11121461
Systemic therapy in node-negative patients: updated findings from NSABP clinical trials. National Surgical Adjuvant Breast and Bowel Project.
B Fisher, C Redmond.
J Natl Cancer Inst Monogr, 1992 Jan 01; (11). PMID: 1627417
erbB-2, p53, and efficacy of adjuvant therapy in lymph node-positive breast cancer.
A D Thor, D A Berry, +9 authors, E T Liu.
J Natl Cancer Inst, 1998 Sep 25; 90(18). PMID: 9747866
Long-term outcomes of invasive ipsilateral breast tumor recurrences after lumpectomy in NSABP B-17 and B-24 randomized clinical trials for DCIS.
Irene L Wapnir, James J Dignam, +8 authors, Norman Wolmark.
J Natl Cancer Inst, 2011 Mar 15; 103(6). PMID: 21398619    Free PMC article.
Highly Cited.
Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer.
Edward H Romond, Edith A Perez, +22 authors, Norman Wolmark.
N Engl J Med, 2005 Oct 21; 353(16). PMID: 16236738
Highly Cited.
A randomized clinical trial evaluating sequential methotrexate and fluorouracil in the treatment of patients with node-negative breast cancer who have estrogen-receptor-negative tumors.
B Fisher, C Redmond, +7 authors, C Sutherland.
N Engl J Med, 1989 Feb 23; 320(8). PMID: 2644531
Risk factors for locoregional recurrence among breast cancer patients: results from International Breast Cancer Study Group Trials I through VII.
A Wallgren, M Bonetti, +12 authors, International Breast Cancer Study Group Trials I through VII.
J Clin Oncol, 2003 Mar 29; 21(7). PMID: 12663706
Tamoxifen in treatment of intraductal breast cancer: National Surgical Adjuvant Breast and Bowel Project B-24 randomised controlled trial.
B Fisher, J Dignam, +11 authors, R H Oishi.
Lancet, 1999 Jun 22; 353(9169). PMID: 10376613
Highly Cited.
Twenty-five-year follow-up of a randomized trial comparing radical mastectomy, total mastectomy, and total mastectomy followed by irradiation.
Bernard Fisher, Jong-Hyeon Jeong, +3 authors, Norman Wolmark.
N Engl J Med, 2002 Aug 23; 347(8). PMID: 12192016
Highly Cited.
Treatment of lymph-node-negative, oestrogen-receptor-positive breast cancer: long-term findings from National Surgical Adjuvant Breast and Bowel Project randomised clinical trials.
Bernard Fisher, Jong-Hyeon Jeong, +5 authors, National Surgical Adjuvant Breast and Bowel Project randomised clinical trials.
Lancet, 2004 Sep 08; 364(9437). PMID: 15351193
Sequential methotrexate and fluorouracil for the treatment of node-negative breast cancer patients with estrogen receptor-negative tumors: eight-year results from National Surgical Adjuvant Breast and Bowel Project (NSABP) B-13 and first report of findings from NSABP B-19 comparing methotrexate and fluorouracil with conventional cyclophosphamide, methotrexate, and fluorouracil.
B Fisher, J Dignam, +12 authors, R G Margolese.
J Clin Oncol, 1996 Jul 01; 14(7). PMID: 8683228
Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: joint analysis of data from NCCTG N9831 and NSABP B-31.
Edith A Perez, Edward H Romond, +7 authors, Norman Wolmark.
J Clin Oncol, 2011 Jul 20; 29(25). PMID: 21768458    Free PMC article.
Highly Cited.
Prognosis after ipsilateral breast tumor recurrence and locoregional recurrences in five National Surgical Adjuvant Breast and Bowel Project node-positive adjuvant breast cancer trials.
Irene L Wapnir, Stewart J Anderson, +5 authors, Norman Wolmark.
J Clin Oncol, 2006 May 02; 24(13). PMID: 16648502
Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer.
Bernard Fisher, Stewart Anderson, +5 authors, Norman Wolmark.
N Engl J Med, 2002 Oct 24; 347(16). PMID: 12393820
Highly Cited.
Predictors of locoregional recurrence after neoadjuvant chemotherapy: results from combined analysis of National Surgical Adjuvant Breast and Bowel Project B-18 and B-27.
Eleftherios P Mamounas, Stewart J Anderson, +6 authors, Norman Wolmark.
J Clin Oncol, 2012 Oct 04; 30(32). PMID: 23032615    Free PMC article.
Highly Cited.
Prognosis after ipsilateral breast tumor recurrence and locoregional recurrences in patients treated by breast-conserving therapy in five National Surgical Adjuvant Breast and Bowel Project protocols of node-negative breast cancer.
Stewart J Anderson, Irene Wapnir, +7 authors, Norman Wolmark.
J Clin Oncol, 2009 Apr 08; 27(15). PMID: 19349544    Free PMC article.
Chemotherapy for isolated locoregional recurrence of breast cancer (CALOR): a randomised trial.
Stefan Aebi, Shari Gelber, +18 authors, CALOR investigators.
Lancet Oncol, 2014 Jan 21; 15(2). PMID: 24439313    Free PMC article.
Findings from recent National Surgical Adjuvant Breast and Bowel Project adjuvant studies in stage I breast cancer.
B Fisher, J H Jeong, +4 authors, N Wolmark.
J Natl Cancer Inst Monogr, 2002 Jan 05; (30). PMID: 11773294
Tamoxifen and chemotherapy for lymph node-negative, estrogen receptor-positive breast cancer.
B Fisher, J Dignam, +10 authors, R G Margolese.
J Natl Cancer Inst, 1997 Dec 09; 89(22). PMID: 9390536
Prevention of invasive breast cancer in women with ductal carcinoma in situ: an update of the National Surgical Adjuvant Breast and Bowel Project experience.
B Fisher, S Land, +3 authors, N Wolmark.
Semin Oncol, 2001 Aug 11; 28(4). PMID: 11498833
Twenty-year follow-up of a randomized study comparing breast-conserving surgery with radical mastectomy for early breast cancer.
Umberto Veronesi, Natale Cascinelli, +5 authors, Ettore Marubini.
N Engl J Med, 2002 Oct 24; 347(16). PMID: 12393819
Highly Cited.
Patterns of locoregional failure in patients with operable breast cancer treated by mastectomy and adjuvant chemotherapy with or without tamoxifen and without radiotherapy: results from five National Surgical Adjuvant Breast and Bowel Project randomized clinical trials.
Alphonse Taghian, Jong-Hyeon Jeong, +4 authors, Norman Wolmark.
J Clin Oncol, 2004 Sep 29; 22(21). PMID: 15452182
Ipsilateral breast tumor recurrence after lumpectomy: is it time to take the bull by the horns?
E P Mamounas.
J Clin Oncol, 2001 Sep 18; 19(18). PMID: 11559716
Adjuvant tamoxifen reduces subsequent breast cancer in women with estrogen receptor-positive ductal carcinoma in situ: a study based on NSABP protocol B-24.
D Craig Allred, Stewart J Anderson, +9 authors, Norman Wolmark.
J Clin Oncol, 2012 Mar 07; 30(12). PMID: 22393101    Free PMC article.
Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.
D J Slamon, B Leyland-Jones, +9 authors, L Norton.
N Engl J Med, 2001 Mar 15; 344(11). PMID: 11248153
Highly Cited.
Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease.
M A Cobleigh, C L Vogel, +8 authors, D J Slamon.
J Clin Oncol, 1999 Nov 24; 17(9). PMID: 10561337
Highly Cited.
Tamoxifen, radiation therapy, or both for prevention of ipsilateral breast tumor recurrence after lumpectomy in women with invasive breast cancers of one centimeter or less.
Bernard Fisher, John Bryant, +9 authors, National Surgical Adjuvant Breast and Bowel Project.
J Clin Oncol, 2002 Oct 16; 20(20). PMID: 12377957
NIH Consensus Development Conference on the Treatment of Early-Stage Breast Cancer. Bethesda, Maryland, June 18-21, 1990.
J Natl Cancer Inst Monogr, 1992 Jan 01; (11). PMID: 1627415
Review.
Locoregional recurrence patterns after mastectomy and doxorubicin-based chemotherapy: implications for postoperative irradiation.
A Katz, E A Strom, +8 authors, M D McNeese.
J Clin Oncol, 2000 Aug 02; 18(15). PMID: 10920129
Significance of ipsilateral breast tumour recurrence after lumpectomy.
B Fisher, S Anderson, +6 authors, R Margolese.
Lancet, 1991 Aug 10; 338(8763). PMID: 1677695
Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors.
B Fisher, J Dignam, +18 authors, H L Lickley.
J Natl Cancer Inst, 1996 Nov 06; 88(21). PMID: 8901851
Highly Cited.
Locoregional failure 10 years after mastectomy and adjuvant chemotherapy with or without tamoxifen without irradiation: experience of the Eastern Cooperative Oncology Group.
A Recht, R Gray, +7 authors, D C Tormey.
J Clin Oncol, 1999 Nov 24; 17(6). PMID: 10561205
Regression of experimental NIS-expressing breast cancer brain metastases in response to radioiodide/gemcitabine dual therapy.
Corinne Renier, John Do, +7 authors, Irene Wapnir.
Oncotarget, 2016 Jul 01; 7(34). PMID: 27363025    Free PMC article.
Poor Prognosis After Second Locoregional Recurrences in the CALOR Trial.
Irene L Wapnir, Shari Gelber, +15 authors, CALOR trial investigators.
Ann Surg Oncol, 2016 Sep 25; 24(2). PMID: 27663567    Free PMC article.
Breast Conservation Therapy Versus Mastectomy in Patients with T1-2N1 Triple-Negative Breast Cancer: Pooled Analysis of KROG 14-18 and 14-23.
Kyubo Kim, Hae Jin Park, +9 authors, Jiyoung Kim.
Cancer Res Treat, 2018 Jan 16; 50(4). PMID: 29334604    Free PMC article.
Tumor cell expression of CD163 is associated to postoperative radiotherapy and poor prognosis in patients with breast cancer treated with breast-conserving surgery.
Stina Garvin, Husam Oda, +2 authors, Ivan Shabo.
J Cancer Res Clin Oncol, 2018 May 05; 144(7). PMID: 29725763    Free PMC article.
Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer.
Joseph A Sparano, Robert J Gray, +27 authors, George W Sledge.
N Engl J Med, 2018 Jun 05; 379(2). PMID: 29860917    Free PMC article.
Highly Cited.
Clinical Outcomes in Early Breast Cancer With a High 21-Gene Recurrence Score of 26 to 100 Assigned to Adjuvant Chemotherapy Plus Endocrine Therapy: A Secondary Analysis of the TAILORx Randomized Clinical Trial.
Joseph A Sparano, Robert J Gray, +26 authors, George W Sledge.
JAMA Oncol, 2019 Oct 01; 6(3). PMID: 31566680    Free PMC article.
Clinical and Genomic Risk to Guide the Use of Adjuvant Therapy for Breast Cancer.
Joseph A Sparano, Robert J Gray, +27 authors, George W Sledge.
N Engl J Med, 2019 Jun 04; 380(25). PMID: 31157962    Free PMC article.
Highly Cited.
Comparison of Oncoplastic Breast-Conserving Therapy and Standard Breast-Conserving Therapy in Early-Stage Breast Cancer Patients.
Yuan Zhou, Yixiao Liu, Yu Wang, Yanfei Wu.
Med Sci Monit, 2021 Jan 02; 27. PMID: 33384404    Free PMC article.